| Oct 31 |
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference
|
| Oct 23 |
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
|
| Oct 21 |
3 US Penny Stocks With Market Caps Under $500M To Consider
|
| Sep 30 |
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
|
| Sep 26 |
Acumen Pharmaceuticals extends collaboration with Lonza
|
| Sep 26 |
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
|
| Sep 25 |
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
|
| Sep 3 |
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
|
| Aug 14 |
Q2 2024 Acumen Pharmaceuticals Inc Earnings Call
|
| Aug 13 |
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript
|
